ArticleMolecular biology reports2013
Positive association of the vascular endothelial growth factor-A +405 GG genotype and poor survival in stage I-II gastric cancer in the Northern Chinese population.
Article in Molecular biology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Correlation of VEGF +405C/G Polymorphism with Gastrointestinal Tract Cancers Risk: An Updated Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- VEGF +405G/C (rs2010963) polymorphisms and digestive system cancer risk: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2014Trial
- Association of VEGFA polymorphisms with the risk of oesophageal cancer in Punjab, India: A case-control study.The Indian journal of medical research · 2024Article
- Genetic Polymorphisms of Vascular Endothelial Growth Factor in Neonatal Pathologies: A Systematic Search and Narrative Synthesis of the Literature.Children (Basel, Switzerland) · 2023Review
- Impact of VEGFA promoter polymorphisms on esophageal cancer risk in North-West Indians: a case-control study.Genes & genomics · 2022Article
- Article
- Lipopolysaccharide Effect on Vascular Endothelial Factor and Matrix Metalloproteinases in Leukemic Cell Lines In vitro.Iranian journal of cancer prevention · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vascular endothelial growth factor-A (VEGF-A) plays an important role in the angiogenesis and prognosis for gastric cancer. In addition, several single-nucleotide polymorphisms (SNPs) in VEGF-A have been shown to affect gene expression and process of angiogenesis. The present study evaluated the correlations between SNPs in VEGF-A and gastric cancer survival. Formalin-fixed paraffin-embedded tissues of 404 gastric cancer patients and blood samples from 404 controls were included in the study. The SNPs -460T/C (rs833061), +405G/C (rs2101963), -7C/T (rs25648) and +936C/T (rs3025039) were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. We showed patients carrying the +405GG genotype had significantly worse survival in the N0 (lymph-node negative), N0L0 (lymph-node negative and lymphovascular-invasion negative) and TNM stage I-II subgroups (P = 0.021, P = 0.007 and P = 0.017, respectively). In addition, haplotype -460T/+405G/-7C and -460C/+405G/-7C carriers showed poor survival in the N0, N0L0 and TNM stage I-II subgroups (P = 0.004, P = 0.030 and P = 0.009 for TGC; P = 0.033, P = 0.049 and P = 0.011 for CGC). Overall, the +405 GG genotype or TGC and CGC haplotypes were correlated with poor survival in TNM stage I-II gastric cancer patients. The +405G/C polymorphism of VEGF-A could be used as a biomarker for molecular staging in stage I-II gastric cancer in Northern China.
Indexed as
Identifiers
23264084What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.